VBI Vaccines Inc.
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vacci… Read more
VBI Vaccines Inc. (VBIVQ) - Total Liabilities
Latest total liabilities as of March 2024: $80.91 Million USD
Based on the latest financial reports, VBI Vaccines Inc. (VBIVQ) has total liabilities worth $80.91 Million USD as of March 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
VBI Vaccines Inc. - Total Liabilities Trend (2020–2023)
This chart illustrates how VBI Vaccines Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
VBI Vaccines Inc. Competitors by Total Liabilities
The table below lists competitors of VBI Vaccines Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Itokk Inc
PINK:IKTO
|
USA | $423.36K |
|
Environmental Solutions Worldwide Inc
PINK:ESWW
|
USA | $10.67 Million |
|
American Oriental Bioengineering Inc
PINK:AOBI
|
USA | $143.95 Million |
|
SPO Global Inc
PINK:SPOM
|
USA | $276.76K |
|
Xalles Holdings Inc
PINK:XALL
|
USA | $2.37 Million |
|
Gold And Gemstone
PINK:GGSM
|
USA | $23.15K |
|
Cableclix USA Inc
PINK:CCLX
|
USA | $2.09 Million |
|
GEROVA Financial Group Ltd
PINK:GVFG
|
USA | $4.34 Million |
Liability Composition Analysis (2020–2023)
This chart breaks down VBI Vaccines Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -14.80 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how VBI Vaccines Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for VBI Vaccines Inc. (2020–2023)
The table below shows the annual total liabilities of VBI Vaccines Inc. from 2020 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $79.42 Million | -12.65% |
| 2022-12-31 | $90.92 Million | +36.94% |
| 2021-12-31 | $66.39 Million | +76.27% |
| 2020-12-31 | $37.67 Million | -- |